Want to see JP:4588 full AI Analyst Report?
4588 Stock Chart & Stats
¥953.00
-¥1.00(-0.20%)
At close: 4:00 PM EST
¥953.00
-¥1.00(-0.20%)
Day’s Range― - ―
52-Week Range¥570.00 - ¥3,695.00
Previous CloseN/A
Volume332.10K
Average Volume (3M)1.52M
Market Cap
¥70.72B
Enterprise Value¥67.07B
Total Cash (Recent Filing)¥1.35B
Total Debt (Recent Filing)¥339.24M
Price to Earnings (P/E)―
Beta2.06
Next Earnings
Aug 07, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-82.50
Shares Outstanding29,319,700
10 Day Avg. Volume2,742,450
30 Day Avg. Volume1,517,566
Financial Highlights & Ratios
PEG Ratio-4.72
Price to Book (P/B)8.90
Price to Sales (P/S)1247.26
P/FCF Ratio-18.32
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Balance-sheet ImprovementThe meaningful expansion of equity and assets alongside a lower debt-to-equity ratio signals a stronger funding base and manageable leverage. That balance-sheet capacity supports ongoing clinical programs and partnering talks, reducing short-term insolvency risk and providing runway for 2–6 month strategic initiatives.
Positive Gross Profit HistoryConsistently positive gross profit — notably ~100% of revenue in 2024 — indicates low direct cost on recognized revenue and the potential for high incremental margins as revenues scale. If operating expenses are managed or offset by partner funding, margin expansion can be durable once top-line recovers.
Partnership-driven Business ModelA collaboration and milestone-based revenue model aligns capital inflows with development milestones, lowering the need for a large commercial footprint. Durable partnerships or license deals can provide non-dilutive funding, risk-sharing on trials, and paths to commercialization without direct sales infrastructure.
Bears Say
Severe Revenue DeclineA multi-year, order-of-magnitude revenue collapse undermines scalable economics and weakens bargaining power with partners. Persistently low top-line receipts constrain funding flexibility, make fixed R&D costs harder to cover, and materially increase execution risk absent a clear catalyst to restore recurring revenue.
Chronic Cash BurnSustained negative operating and free cash flow at material magnitudes implies ongoing reliance on external financing. That persistent burn creates dilution risk, constrains strategic optionality, and can force prioritization or pauses in clinical programs if new funding or partnership milestones do not materialize.
Large Operating LossesConsistent, deep operating losses erode equity and limit the company's ability to self-fund development. Without a sustained revenue rebound or major partner-funded milestones, operating deficits will pressure cash reserves and may necessitate restructuring, asset sales, or dilutive financing over a medium-term horizon.
Oncolys BioPharma, Inc. News
4588 FAQ
What was Oncolys BioPharma, Inc.’s price range in the past 12 months?
Oncolys BioPharma, Inc. lowest stock price was ¥570.00 and its highest was ¥3695.00 in the past 12 months.
What is Oncolys BioPharma, Inc.’s market cap?
Oncolys BioPharma, Inc.’s market cap is ¥70.72B.
When is Oncolys BioPharma, Inc.’s upcoming earnings report date?
Oncolys BioPharma, Inc.’s upcoming earnings report date is Aug 07, 2026 which is in 14 days.
How were Oncolys BioPharma, Inc.’s earnings last quarter?
Oncolys BioPharma, Inc. released its earnings results on May 08, 2026. The company reported -¥14.16 earnings per share for the quarter, missing the consensus estimate of N/A by -¥14.16.
Is Oncolys BioPharma, Inc. overvalued?
According to Wall Street analysts Oncolys BioPharma, Inc.’s price is currently Overvalued.
Does Oncolys BioPharma, Inc. pay dividends?
Oncolys BioPharma, Inc. does not currently pay dividends.
What is Oncolys BioPharma, Inc.’s EPS estimate?
Oncolys BioPharma, Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Oncolys BioPharma, Inc. have?
Oncolys BioPharma, Inc. has 29,319,700 shares outstanding.
What happened to Oncolys BioPharma, Inc.’s price movement after its last earnings report?
Oncolys BioPharma, Inc. reported an EPS of -¥14.16 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 2.819%.
Which hedge fund is a major shareholder of Oncolys BioPharma, Inc.?
Currently, no hedge funds are holding shares in JP:4588
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Oncolys BioPharma, Inc.
Oncolys BioPharma Inc. is a biotechnology firm dedicated to the research, development, manufacturing, sales, and distribution of oncolytic viruses, pharmaceutical drugs, and diagnostic agents for tumors across Japan, other Asian regions, and the United States. Its robust pipeline features Telomelysin (OBP-301), an oncolytic adenovirus, currently in Phase II clinical trials for the treatment of gastric, gastroesophageal junction, head and neck, and esophageal cancers, and in Phase I trials for hepatocellular carcinoma. Other key developments include OBP-702, a telomerase-specific oncolytic adenovirus in preclinical stages for solid tumors; OBP-2011, also preclinical, targeting SARS-CoV-2 infection; OBP-601 (Censavudine), a nucleotide reverse transcriptase inhibitor that has completed Phase IIb clinical trials for HIV; and OBP-801, a histone deacetylase inhibitor, which is in Phase I clinical trials for solid tumors and preclinical assessment for ophthalmic applications. Additionally, the company is advancing TelomeScan (OBP-401 and OBP-1101), a cancer detection drug designed to identify living circulating tumor cells in cancer patients' blood. Oncolys BioPharma also offers diagnostic medications and inspection services. The company boasts various licensing and collaborative agreements with institutions such as Okayama University, Osaka University, Kyoto Prefectural University of Medicine, Kagoshima University, Astellas Pharma Inc., Yale University, Biologics Consulting Group, Inc., Lonza Houston, Inc., Medigen Biotechnology Corp., and Liquid Biotech USA, Inc. Founded in 2004, Oncolys BioPharma Inc. is based in Tokyo, Japan.